Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480802 | 1.00 | NOS1 (0.47) | NOS1DYRK1ASIRT2HSP90AA1IDO1 | |
| SCHEMBL14831000 | 0.76 | MAPT (0.47) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL16433147 | 0.73 | ALDH1A1 (0.41) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL30174455 | 0.71 | CCR1 (0.44) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL30327614 | 0.71 | NOS1 (0.47) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL17673803 | 0.71 | FGFR1 (0.41) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL17673782 | 0.71 | NOS1 (0.47) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL20389659 | 0.69 | PLK4 (0.48) | NOS1DYRK1AKDM4EALDH1A1GAA | |
| SCHEMBL29882851 | 0.69 | PLK4 (0.48) | NOS1DYRK1AKDM4EALDH1A1GAA | |
| SCHEMBL12726379 | 0.68 | MAPT (0.39) | NOS1DYRK1AHSP90AA1IDO1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118019743-A | Compounds useful as SHP2 inhibitors, methods of preparation and uses thereof | 甘李药业股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| WO-2023051648-A1 | COMPOUND AS SHP2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 甘李药业股份有限公司 | 2023-04-06 | — | — | WO | claimed |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | AJAX THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250339444-A1 | Methods and Compositions for Treating Fatty Liver and Viral Infections | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025101588-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025079989-A1 | PYRAZOLO[3,4-B]PYRIDINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사유한양행 | 2025-04-17 | — | — | WO | disclosed |
| US-7524845-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524845-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| WO-2008147822-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | JAK2, JAK1, JAK3 | NOS1 387/4885DYRK1A 349/4885SIRT2 3563/4885 |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | NOS1 1987/4885DYRK1A 4319/4885SIRT2 2958/4885 |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | NOS1 1108/4885DYRK1A 2883/4885SIRT2 1453/4885 |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CCR1, CCR3, CCR4 | NOS1 1987/4885DYRK1A 4319/4885SIRT2 2958/4885 |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | CCR1, CCR6, CCRL2 | NOS1 3221/4885DYRK1A 1987/4885SIRT2 3322/4885 |
| US-20250339444-A1 | Methods and Compositions for Treating Fatty Liver and Viral Infections | FABP1, FABP4, LIPC | NOS1 4585/4885DYRK1A 4653/4885SIRT2 3951/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | NOS1 4710/4885DYRK1A 2261/4885SIRT2 2456/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | NOS1 3611/4885DYRK1A 1207/4885SIRT2 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.